# A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

> **NCT04210219** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 85 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** JNJ-64264681

## Key facts

- **NCT ID:** NCT04210219
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-02
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-05-28
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04210219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04210219, "A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04210219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*